hotspot -WSS

hotspot

author：fashion 2025-10-03 00:08:19 - browse：5

Alphabet’s life sciences company Verily has scored its first Centers for Disease Control and Prevention contract, a high profile job leaders hope will boost its brand in public health as well as its nascent wastewater surveillance business, executives told STAT.

Under the up-to-five year, $38 million contract, Verily will collect samples from hundreds of wastewater treatment centers across the country, analyze them for Covid-19 and the mpox virus at its South San Francisco lab, and return the data to CDC within 36 hours of collecting the samples. The contract is limited to those two pathogens but the company is prepared to analyze more if needed, leaders said.

The contract comes as Verily struggles to turn a profit among various disparate health care offerings, like value-based care analytics for health systems, clinical trial software and even an in-person substance use rehabilitation center in Ohio. Despite several prominent hires and a vast number of projects, the company has yet to forge a sustainable business.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

WSS

With FDA staff opposed to Sarepta therapy, top official intervened

Woman returns to dialysis after doctors remove transplanted pig kidney

With trial win, GSK could get blood cancer drug back on market

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Letters to First Opinion on caregivers, digital health, and more

entertainment

hotspot

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

NIH documents show early flaws of $1.6 billion long Covid program

Dobbs anniversary: the lost opportunity of abortion as health care

Colonoscopy at 40? Study finds a possible benefit

Medicare details structure of new drug price negotiation program

With trial win, GSK could get blood cancer drug back on market

As demand for Covid shots wanes, Moderna seeks its next success

Why we need to separate burnout from moral injury in health care

Bright Health sells Medicare Advantage business to Molina

FDA's Pazdur wants cancer trials to range beyond China alone

focus

ASCO: Palliative care found as helpful given virtually as in person

Letters to First Opinion on caregivers, digital health, and more

With trial win, GSK could get blood cancer drug back on market

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

The science behind Janet Jackson's pregnancy at 49

leisure time

leisure time

leisure time

leisure time